{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:23:48Z","timestamp":1769552628086,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K07179"],"award-info":[{"award-number":["20K07179"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10637-023-01414-y","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T05:02:25Z","timestamp":1701838945000},"page":"44-52","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-2841","authenticated-orcid":false,"given":"Daiki","family":"Tsuji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Nakagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itsuki","family":"Yonezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yokokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Hatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyasu","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kogure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinobu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misa","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"1414_CR1","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1007\/s00520-012-1448-1","volume":"20","author":"P Fern\u00e1ndez-Ortega","year":"2012","unstructured":"Fern\u00e1ndez-Ortega P, Caloto MT, Chirveches E, Marquilles R, Francisco JS, Quesada A et al (2012) Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients\u2019 quality of life. Support Care Cancer 20:3141\u20133148. https:\/\/doi.org\/10.1007\/s00520-012-1448-1","journal-title":"Support Care Cancer"},{"key":"1414_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00520-009-0797-x","volume":"19","author":"TA Burke","year":"2011","unstructured":"Burke TA, Wisniewski T, Ernst FR (2011) Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer 19:131\u2013140. https:\/\/doi.org\/10.1007\/s00520-009-0797-x","journal-title":"Support Care Cancer"},{"key":"1414_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M et al (2016) Olanzapine for the Prevention of Chemotherapy-Induced nausea and vomiting. N Engl J Med 375:134\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa1515725","journal-title":"N Engl J Med"},{"key":"1414_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T et al (2020) Olanzapine 5\u00a0mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242\u2013249. https:\/\/doi.org\/10.1016\/S1470-2045(19)30678-3","journal-title":"Lancet Oncol"},{"key":"1414_CR5","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1007\/s00520-020-05935-7","volume":"29","author":"R Chow","year":"2021","unstructured":"Chow R, Herrstedt J, Aapro M, Chiu L, Lam H, Prsic E et al (2021) Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer 29:3439\u20133459. https:\/\/doi.org\/10.1007\/s00520-020-05935-7","journal-title":"Support Care Cancer"},{"key":"1414_CR6","unstructured":"Ettinger DS, Huber S, Kris MG, Levy M, McNulty R, Noonan KR, Stucky-Marshall L, Urba S, Wood JG (1997) NCCN antiemesis practice guidelines. Oncol (Williston Park). 11A:57\u201389"},{"key":"1414_CR7","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/annonc\/mds021","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M, Molassiotis A, Dicato M, Pel\u00e1ez I, Rodr\u00edguez-Lescure \u00c1, Pastorelli D et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23:1986\u20131992. https:\/\/doi.org\/10.1093\/annonc\/mds021","journal-title":"Ann Oncol"},{"key":"1414_CR8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00520-018-4403-y","volume":"27","author":"N Abunahlah","year":"2016","unstructured":"Abunahlah N, Sancar M, Dane F, \u00d6zyavuz MK (2016) Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life. Support Care Cancer 27:1139\u20131147. https:\/\/doi.org\/10.1007\/s00520-018-4403-y","journal-title":"Support Care Cancer"},{"key":"1414_CR9","doi-asserted-by":"publisher","first-page":"73 \u201378","DOI":"10.1007\/s00520-019-04778-1","volume":"28","author":"H Woopen","year":"2020","unstructured":"Woopen H, Richter R, Chekerov R, Inci G, Alavi S, Grabowski JP et al (2020) Prognostic role of chemotherapy-induced nausea and vomiting in recurrent Ovarian cancer patients: results of an individual participant data meta-analysis in 1213 support Care. Cancer 28:73\u201378. https:\/\/doi.org\/10.1007\/s00520-019-04778-1","journal-title":"Cancer"},{"key":"1414_CR10","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27:v119. https:\/\/doi.org\/10.1093\/annonc\/mdw270","journal-title":"Ann Oncol"},{"key":"1414_CR11","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA et al (2020) Antiemetics: ASCO Guideline Update. J Clin Oncol 38:2782\u20132797. https:\/\/doi.org\/10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"1414_CR12","unstructured":"Ettinger DS, Berger MJ, Agarwal R, Anand S, Bagegni NA, Barbour S et al (2023) NCCN Guidelines Version 2. Antiemesis. https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf"},{"key":"1414_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","volume":"94","author":"J Vardy","year":"2006","unstructured":"Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011\u20131015. https:\/\/doi.org\/10.1038\/sj.bjc.6603048","journal-title":"Br J Cancer"},{"key":"1414_CR14","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.4143\/crt.2015.464","volume":"48","author":"Y Jeong","year":"2016","unstructured":"Jeong Y, Han HS, Lee HD, Yang J, Jeong J, Choi MK et al (2016) A pilot study evaluating Steroid-Induced Diabetes after antiemetic dexamethasone therapy in chemotherapy-treated Cancer patients. Cancer Res Treat 48:1429\u20131437. https:\/\/doi.org\/10.4143\/crt.2015.464","journal-title":"Cancer Res Treat"},{"key":"1414_CR15","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1634\/theoncologist.2016-0308","volume":"22","author":"M Nakamura","year":"2017","unstructured":"Nakamura M, Ishiguro A, Muranaka T, Fukushima H, Yuki S, Ono K et al (2017) A prospective observational study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01). Oncologist 22:592\u2013600. https:\/\/doi.org\/10.1634\/theoncologist.2016-0308","journal-title":"Oncologist"},{"key":"1414_CR16","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A et al (2018) Impact of baseline steroids on efficacy of programmed cell Death-1 and programmed death-ligand 1 blockade in patients with non-small-cell Lung Cancer. J Clin Oncol 36:2872\u20132878. https:\/\/doi.org\/10.1200\/JCO.2018.79.0006","journal-title":"J Clin Oncol"},{"key":"1414_CR17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","volume":"27","author":"JB Iorgulescu","year":"2021","unstructured":"Iorgulescu JB, Gokhale PC, Speranza MC, Eschle BK, Poitras MJ, Wilkens MK et al (2021) Concurrent dexamethasone limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clin Cancer Res 27:276\u2013287. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2291","journal-title":"Clin Cancer Res"},{"key":"1414_CR18","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1634\/theoncologist.2019-0133","volume":"24","author":"Y Okada","year":"2019","unstructured":"Okada Y, Oba K, Furukawa N, Kosaka Y, Okita K, Yuki S et al (2019) One-day Versus three-day dexamethasone in combination with Palonosetron for the Prevention of Chemotherapy-Induced nausea and vomiting: a systematic review and individual Patient Data-based Meta-analysis. Oncologist 24:1593\u20131600. https:\/\/doi.org\/10.1634\/theoncologist.2019-0133","journal-title":"Oncologist"},{"key":"1414_CR19","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1186\/s12885-019-6454-y","volume":"19","author":"L Celio","year":"2019","unstructured":"Celio L, Bonizzoni E, Zattarin E, Codega P, de Braud F, Aapro M (2019) Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence. BMC Cancer 19:1268. https:\/\/doi.org\/10.1186\/s12885-019-6454-y","journal-title":"BMC Cancer"},{"key":"1414_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1740774520975120","volume":"18","author":"E Basch","year":"2021","unstructured":"Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P et al (2021) Composite grading algorithm for the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Clin Trials 18:104\u2013114. https:\/\/doi.org\/10.1177\/1740774520975120","journal-title":"Clin Trials"},{"key":"1414_CR21","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1084\/jem.20190738","volume":"216","author":"A Tokunaga","year":"2019","unstructured":"Tokunaga A, Sugiyama D, Maeda Y, Warner AB, Panageas KS, Ito S et al (2019) Selective inhibition of low-affinity memory CD8\u2009+\u2009T cells by corticosteroids. J Exp Med 216:2701\u20132713. https:\/\/doi.org\/10.1084\/jem.20190738","journal-title":"J Exp Med"},{"key":"1414_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/onco.13680","volume":"26","author":"T Janowitz","year":"2021","unstructured":"Janowitz T, Kleeman S, Vonderheide RH (2021) Reconsidering dexamethasone for Antiemesis when combining chemotherapy and immunotherapy. Oncologist 26:269\u2013273. https:\/\/doi.org\/10.1002\/onco.13680","journal-title":"Oncologist"},{"key":"1414_CR23","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P et al (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 28:1260\u20131267. https:\/\/doi.org\/10.1093\/annonc\/mdx100","journal-title":"Ann Oncol"},{"key":"1414_CR24","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","volume":"27","author":"K Suzuki","year":"2016","unstructured":"Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R et al (2016) Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol 27:1601\u20131606. https:\/\/doi.org\/10.1093\/annonc\/mdw220","journal-title":"Ann Oncol"},{"key":"1414_CR25","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","volume":"36","author":"Y Ito","year":"2018","unstructured":"Ito Y, Tsuda T, Minatogawa H, Kano S, Sakamaki K, Ando M et al (2018) Placebo-Controlled, double-blinded phase III study comparing dexamethasone on Day 1 with dexamethasone on days 1 to 3 with combined Neurokinin-1 receptor antagonist and Palonosetron in High-Emetogenic Chemotherapy. J Clin Oncol 36:1000\u20131006. https:\/\/doi.org\/10.1200\/JCO.2017.74.4375","journal-title":"J Clin Oncol"},{"key":"1414_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","volume":"104","author":"I Sekine","year":"2013","unstructured":"Sekine I, Segawa Y, Kubota K, Saeki T (2013) Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci 104:711\u2013717. https:\/\/doi.org\/10.1111\/cas.12146","journal-title":"Cancer Sci"},{"key":"1414_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","volume":"23","author":"T Yanai","year":"2018","unstructured":"Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K et al (2018) A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 23:382\u2013388doi. https:\/\/doi.org\/10.1007\/s10147-017-1200-4","journal-title":"Int J Clin Oncol"},{"key":"1414_CR28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00520-015-2829-z","volume":"24","author":"M Abe","year":"2016","unstructured":"Abe M, Hirashima Y, Kasamatsu Y, Kado N, Komeda S, Kuji S et al (2016) Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Support Care Cancer 24:675\u2013682doi. https:\/\/doi.org\/10.1007\/s00520-015-2829-z","journal-title":"Support Care Cancer"},{"key":"1414_CR29","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJMp0911494","volume":"362","author":"E Basch","year":"2010","unstructured":"Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362:865\u2013869. https:\/\/doi.org\/10.1056\/NEJMp0911494","journal-title":"N Engl J Med"},{"key":"1414_CR30","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","volume":"33","author":"E Sarnes","year":"2011","unstructured":"Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D (2011) Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther 33:1413\u20131432. https:\/\/doi.org\/10.1016\/j.clinthera.2011.09.009","journal-title":"Clin Ther"},{"key":"1414_CR31","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","volume":"77","author":"GV Papatheodoridis","year":"2022","unstructured":"Papatheodoridis GV, Lekakis V, Voulgaris T, Lampertico P, Berg T, Chan HLY et al (2022) Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion. J Hepatol 77:1670\u20131689. https:\/\/doi.org\/10.1016\/j.jhep.2022.07.003","journal-title":"J Hepatol"},{"key":"1414_CR32","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/jhep.2003.50220","volume":"37","author":"AL Cheng","year":"2003","unstructured":"Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ et al (2003) Steroid-free chemotherapy decreases risk of Hepatitis B virus (HBV) reactivation in HBV-carriers with Lymphoma. Hepatology 37:1320\u20131328. https:\/\/doi.org\/10.1053\/jhep.2003.50220","journal-title":"Hepatology"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01414-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01414-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01414-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T14:04:39Z","timestamp":1708956279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01414-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1414"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01414-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"17 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects published by Japan\u2019s Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare, Japan, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the institutional review board at the University of Shizuoka and each participating site.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}